VIDEO: Insight into FOLFOXIRI plus panitumumab for certain patients with colorectal cancer
Click Here to Manage Email Alerts
In this video, Michael Cecchini, MD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs. mFOLFOX6 plus panitumumab as initial treatment of unresectable RAS and BRAF wild-type metastatic colorectal cancer.
"There was no increase in response rate, which was their primary endpoint, despite being a phase 3 study with more than 400 patients; also no significant improvements in PFS or OS," Cecchini, assistant professor of medical oncology at Yale School of Medicine, said of the study presented at ASCO Annual Meeting.
"That shows us that FOLFOXIRI plus panitumumab or FOLFOXIRI potentially with cetuximab isn't really a treatment we should be offering our patients routinely," Cecchini said.
Collapse
Read more about
Click Here to Manage Email Alerts